BACKGROUND: Human papillomavirus 16 (HPV16) E6 antibodies may be an early marker of the diagnosis and recurrence of human papillomavirus-driven oropharyngeal cancer (HPV-OPC). METHODS: This study identified 161 incident oropharyngeal cancer (OPC) cases diagnosed at the University of Pittsburgh (2003Pittsburgh ( -2013 with pretreatment serum. One hundred twelve had preexisting clinical HPV testing with p16 immunohistochemistry and HPV in situ hybridization (87 were dual-positive [HPV-OPC], and 25 were dualnegative [HPV-negative]); 62 had at least 1 posttreatment serum sample. Eighty-six of the 161 tumors were available for additional HPV16 DNA/RNA testing (45 were dual-positive [HPV16-OPC], and 19 were dual-negative [HPV16-negative). HPV16 E6 antibody testing was conducted with multiplex serology. The following were evaluated: 1) the sensitivity and specificity of HPV16 E6 serology for distinguishing HPV-OPC and HPV16-OPC from HPV-negative OPC, 2) HPV16 E6 antibody decay after treatment with linear models accommodating correlations in variance estimates, and 3) pre-and posttreatment HPV16 E6 levels and the risk of recurrence with Cox proportional hazards models. RESULTS: Seventy-eight of 87 HPV-OPCs were HPV16 E6-seropositive (sensitivity, 89.7%; 95% confidence interval [CI], 81.3%-95.2%), and 24 of 25 HPV-negative OPCs were HPV16 E6-seronegative (specificity, 96.0%; 95% CI, 79.6%-99.9%). Forty-two of 45 HPV16-OPCs were HPV16 E6-seropositive (sensitivity, 93.3%; 95% CI, 81.7%-98.6%), and 18 of 19 HPV16-negative OPCs were HPV16 E6-seronegative (specificity, 94.7%; 95% CI, 74.0%-99.9%). Posttreatment HPV16 E6 antibody levels did not decrease significantly from the baseline (P 5 .575; median follow-up, 307 days) and were not associated with the risk of recurrence. However, pretreatment HPV16 E6 seropositivity was associated with an 86% reduced risk of local/regional recurrence (hazard ratio, 0.14; 95% CI, 0.03-0.68; P 5 .015). CONCLUSIONS: HPV16 E6 antibodies may have potential clinical utility for the diagnosis and/ or prognosis of HPV-OPC. Cancer 2017;123:4382-90.
INTRODUCTION
The incidence of human papillomavirus-driven oropharyngeal cancer (HPV-OPC) has risen by 225% since the 1980s within the United States and now accounts for 75% of all oropharyngeal cancers (OPCs). 1 Although treatment for HPV-OPC is often curative, severe treatment-related morbidities include permanent difficulty with swallowing/eating. 2 Recently, there has been a focus on reducing this morbidity through the development of de-escalated treatment protocols and screening methods for early detection. However, the implementation of de-escalated treatment protocols has been hindered by the inability to identify those patients at highest risk for recurrence, for whom de-escalation would be ill advised, and the development of screening methods has been hindered by the inability to identify those at highest risk for OPC.
Human papillomavirus 16 (HPV16) E6 antibody positivity has recently been identified as a promising biomarker for both the diagnosis and prognosis of OPC. A prospective European-based study found that 34.8% of patients with OPC were seropositive for HPV16 E6, whereas only 0.6% of cancer-free controls were. Importantly, HPV16 E6 antibodies were present more than 10 years before the diagnosis. 3 We recently confirmed these findings in a United States-based cohort. 4 Several studies also have suggested that both pre-and posttreatment HPV16 E6 levels may be associated with the risk of HPV-OPC recurrence. [5] [6] [7] [8] In many of these serum-based studies, 3, [5] [6] [7] 9, 10 information regarding the HPV status of the tumors was not available, or the HPV status was assessed with non-goldstandard methods. Thus, the sensitivity of HPV16 E6 seropositivity for detecting the subset of tumors caused by an HPV infection is unknown. Before HPV16 E6 antibodies are considered as a potential tool for the early detection and/or prognosis of HPV-OPC, larger studies using highly specific HPV16 E6 serologic assays and goldstandard methods for assigning the HPV tumor status are needed.
Using a large sample of OPC tumors (n 5 161) from a clinic-based US population, the objectives of this study were to 1) determine both the sensitivity and specificity of HPV16 E6 seropositivity for detecting HPV-OPC and 2) determine the association between pre-and posttreatment HPV16 E6 levels and the risk of HPV-OPC recurrence using gold-standard methods for HPV serology and the assignment of the HPV tumor status. We used the same highly specific multiplex serology assay used in the initial discovery and validation of HPV16 E6 seropositivity as an early marker of OPC. 3, 4 In addition, to minimize misclassification, we used both clinical and research gold-standard methods for assigning the HPV tumor status: combined p16 immunohistochemistry (IHC) and HPV in situ hybridization (ISH) and combined HPV DNA and RNA analysis, respectively.
MATERIALS AND METHODS

Study Population
Incident, previously untreated cases of OPC were identified with an institutional review board-approved protocol (University of Pittsburgh Cancer Institute 99-069) that collects baseline serum data at the University of Pittsburgh Cancer Institute; all patients provided written informed consent.
Since the establishment of the biobank in 2000, a total of 1462 patients with OPC (International Classification of Diseases, Tenth Revision codes C01.0, C02.4, C05.1, C05.2, C05.8, C09.0, C09.1, C09.8, C09.9, C10.0, C10.2, C10.3, C10.8, C10.9, and C14.0) were treated; 939 (64%) were enrolled as part of the tissue banking study. Of the 860 incident cases, 720 (84%) had serum samples collected before treatment, and 112 of these (16%) had concurrent p16 IHC and HPV ISH test  results available as part of their clinical management. HPV antibody testing was conducted on pretreatment serum samples from all incident cases of HPV-OPC (87 p16 and HPV ISH dual-positives) and HPV-negative OPC (25 p16 and HPV ISH dual-negatives). Testing of serial samples was conducted for the subset of patients (35 of 87) who had 1 to 2 posttreatment samples available. In addition, we chose to test serial samples from all HPVindeterminate OPCs (discordant or missing p16 IHC and HPV ISH results) for which posttreatment samples were available under the assumption that the majority would be HPV16 E6-seropositive before treatment; thus, increasing our power to assess the association between change in HPV16 E6 levels posttreatment and risk of recurrence. However, serum samples from 22 HPVindeterminate patients were erroneously tested under the belief that they had posttreatment serial samples (Supporting Fig. 1 [see online supporting information]).
Eighty-six tumors were recovered for HPV16 type--specific DNA and RNA testing. Those with concordant HPV16 DNA/RNA positive results were defined as HPV16-driven (HPV16-OPC), those with concordant negative results were defined as HPV16-negative, and those with discordant results were considered indeterminate.
Laboratory Methods
Serologic testing
Multiplex serologic testing was performed at the German Cancer Research Center (Heidelberg, Germany) by staff blinded to the HPV status of the patients.
11-14 Antigens were affinity-purified, bacterially expressed fusion proteins with N-terminal glutathione S-transferase. Samples were analyzed for antibodies against HPV16 L1, E1, E2, E4, E6, and E7 and the E6 protein from HPV6, HPV11, HPV18, HPV31, HPV33, HPV45, and HPV58. Antibody levels were quantified at a 1:100 serum dilution as the median fluorescence intensity (MFI) and were dichotomized as positive or negative on the basis of previously defined cutpoints. 3, 15 Clinical HPV testing As part of the clinical management, p16 overexpression and HPV DNA ISH were available for a subset of patients. p16 IHC was conducted on deparaffinized tissue sections with the monoclonal antibody clone G175-405 against p16INK4 (dilution, 1:200; BD Pharmingen, San Diego, California); immunoreactivity in 70% of cells was considered positive. 16, 17 ISH was performed with a probe set specific for 10 HPV types (Dako Cytomation, Carpinteria, California).
HPV type-specific testing
Formalin-fixed, paraffin-embedded tissue samples were consecutively sectioned for DNA and RNA analysis; the first and last sections were stained with hematoxylin and eosin to verify the presence of a tumor. 18 DNA and RNA were extracted from formalin-fixed, paraffin-embedded sections as previously described 18 ; water samples were included to monitor possible cross-contamination. The HPV DNA analysis was performed with multiplex papillomavirus genotyping, 19, 20 which homogeneously amplified and specifically detected 51 HPV types, 3 subtypes, and cellular b-globin as an internal DNA quality control. Samples that were positive for HPV and/or positive for cellular b-globin DNA were considered DNA-valid. The HPV RNA analysis (ie, the detection of viral transcripts) was performed with HPV type-specific reverse transcription-polymerase chain reaction and hybridization assays 18 developed for 20 distinct HPV types. These assays amplify HPV E6*I and ubiquitin C complementary DNA as a cellular messenger RNA quality control. Specimens that were positive for HPV E6*I and/or ubiquitin C messenger RNA were considered RNA-valid.
Statistical Analyses
Patient characteristics were evaluated overall and by the HPV tumor status. The proportion of HPV-OPC cases seropositive for HPV16 antibodies (sensitivity) and the proportion of HPV-negative OPCs seronegative for HPV16 antibodies (specificity) were calculated for all HPV16 proteins analyzed; confidence intervals (CIs) were estimated with an exact binomial method. The overall sensitivity and specificity of HPV16 E6 antibodies for HPV16-OPC and overall OPC (regardless of the HPV tumor status) were calculated with the same methods. The associations between pretreatment HPV16 E6 seropositivity and 1) the risk of overall recurrence (local/regional and distant metastasis combined), 2) the risk of local/ regional and distant metastasis considered separately, and 3) overall survival were evaluated via estimations of hazard ratios (HRs) and 95% CIs from Cox proportional hazards models. We used years since the cancer diagnosis as the time variable. For the risk of overall recurrence, the follow-up ended at the time (years) of first recurrence (local/regional or distant) or the time of censoring; the censoring event was death or last follow-up. For the risk of local/regional recurrence, the follow-up ended at the time of first local/regional recurrence (the event of interest) or at the time of the diagnosis of metastasis, death, or last follow-up (all censoring events). To estimate the risk of metastasis, the follow-up time ended at the diagnosis of first metastasis, local/regional recurrence, death, or last follow-up. To assess the risk of death from any cause, the only censoring event was last follow-up. We chose Cox regression for estimating the risk of recurrence because Prentice et al 21 showed that the cause-specific hazard can be estimated by the treatment of all other competing events as censoring events. This approach does not require any independence assumption for the main outcome and competing events to obtain valid and unbiased relative risk estimates. The proportional hazards assumption was confirmed for each model. HPV16 E6 antibody decay was evaluated in linear models accommodating correlations over time in the variance estimate. 22, 23 We also modeled HPV16 E6 antibody levels coded in tertiles as a time-dependent variable in a Cox regression model to incorporate posttreatment HPV16 E6 antibody levels to assess the risk of recurrence among all patients who were HPV16 E6-seropositive before treatment. All analyses were performed with Stata IC 14 and SAS 9.4.
RESULTS
Patient Characteristics
A total of 161 patients were included in this analysis; 112 (69.6%) had prior clinical testing for HPV (25 [22.3%] had HPV-negative OPC and 87 [77.7%] had HPV-OPC), and 49 (30.4%) had an indeterminate tumor status (Table 1) . Overall, the median age at diagnosis was 58 years (interquartile range, 51-64 years); the majority of the patients were male (80.8%), white (96.9%), and at an advanced stage (77.0% at stage III or IV according to the 7th edition of the American Joint Committee on Cancer [AJCC] guidelines). Compared with patients with HPVnegative OPC, patients with HPV-OPC tended to be younger and male, to be nonsmokers and nondrinkers, and to be an advanced stage (7th edition of the AJCC guidelines). However, according to the 8th edition of the AJCC guidelines, the majority of the HPV-OPC patients would have been considered to be at stage I (78.2%). Patients with an indeterminate HPV tumor status most closely resembled those with HPV-OPC.
Sensitivity and Specificity of HPV16 Serology for HPV-OPC
Of the 6 HPV16 proteins assessed, HPV16 E6 antibodies were the most sensitive; 78 of 87 HPV-OPC patients were HPV16 E6-seropositive (sensitivity, 89.7%; 95% CI, Original Article 81.3%-95.2%; Table 2 ). Twenty-four of 25 HPV-negative OPC patients were HPV16 E6-seronegative (specificity, 96.0%; 95% CI, 79.6%-99.9%). The sensitivity and specificity of the other HPV16 antibodies ranged from 35.6% to 83.9% and from 80.0% to 96.0%, respectively. The sensitivity of HPV serology for HPV-OPC increased when HPV16 seropositivity was expanded to include seropositivity for 3 or more early proteins (sensitivity, 93.1%; 95% CI, 85.6%-97.4%). Of the 9 HPV-OPC patients without detectable HPV16 E6 antibodies, 8 were seropositive against at least 1 other HPV16 E protein, 4 were seropositive against 1 or more E6 proteins from oncogenic non-HPV16 types, and 1 was seronegative for all HPV proteins tested. The 1 HPV16 E6-seropositive patient with an HPV-negative tumor was seroreactive against all HPV16 proteins evaluated (Supporting Table 1 [see online When all retrieved tumors, regardless of prior p16 IHC and HPV ISH testing (n 5 64), were considered, the sensitivity and specificity estimates were 93.3% (95% CI, 81.7%-98.6%) and 94.7% (95% CI, 74.0%-99.9%), respectively ( Table 3 ). The sensitivity of HPV16 E6 antibodies with various definitions of the HPV tumor status is presented in Supporting Table 3 (see online supporting information). From the 10 patients whose HPV16 E6 serology and clinical HPV tumor status were discordant, 6 tumors were retrieved; all originated from HPV-OPC patients who were HPV16 E6-seronegative. One tumor was HPV16-driven, 2 were HPV16 DNA-positive, and 3 were driven by other HPV types (Supporting Table 1 [see online supporting information]).
The sensitivity and specificity of HPV E6 serology for non-HPV16-driven tumors were also assessed. One of 3 HPV18-OPC cases was HPV18 E6-seropositive (sensitivity, 33%), and 78 of 79 HPV18-negative cases were HPV18 E6-seronegative (specificity, 99%). Both HPV33-OPC cases were HPV33 E6-seropositive (sensitivity, 100%), and 50 of 80 HPV33-negative OPC cases were HPV33 E6-seronegative (specificity, 63%). Original Article
HPV16 Antibody Levels and Risk of Recurrence
Eleven of 87 HPV-OPC patients (12.6%) experienced recurrence (6 local/regional recurrences and 5 distant metastases; median follow-up, 3.6 years; interquartile range, 2.1-5.2 years). Pretreatment HPV16 E6 seropositivity was associated with an 86% reduced risk of local/ regional recurrence (HR, 0.14; 95% CI, 0.03-0.68; P 5 .015). No association between pretreatment HPV16 E6 seropositivity and distant metastasis or overall survival was observed (Table 4) . A similar HR estimate was observed for local/regional recurrence when it was restricted to patients with HPV16-OPC, although because of the smaller sample size, it was not significant (P 5 .065). Changes in HPV16 E6 antibody levels were evaluated among 53 patients with serial samples who were HPV16 E6-seropositive at diagnosis. HPV16 E6 MFI levels did not significantly decrease over time (Fig. 1) ; the unadjusted estimate was -161.2 MFI/y (95% CI, -724.6 to 402.1; P 5 .575). Seven of the 53 patients experienced recurrence (5 local/regional recurrences and 2 distant metastases). Changes in HPV16 E6 levels after treatment were not associated with recurrence of any type; all P values were >.05 (Supporting Fig. 3 [see online supporting information]).
DISCUSSION
We used a highly specific multiplex serology assay and both clinical and research gold-standard methods for assigning the HPV tumor status to assess the sensitivity of HPV16 E6 serology for HPV-OPC and HPV16-OPC. Using the clinical gold-standard method of concordant p16 IHC and HPV ISH testing, we found that the sensitivity and specificity of HPV16 E6 antibodies for HPV-OPC were high (89.7% and 96.0%, respectively). The sensitivity was further increased when we considered tumors driven specifically by HPV16, as defined by the research gold-standard method of concordant HPV16 DNA/RNA testing (sensitivity, 93.3%). Although we did not observe a significant decrease in HPV16 E6 antibody levels after treatment or an association between changes in antibody levels after treatment and the risk of recurrence, HPV-OPC patients who failed to mount an HPV16 E6 antibody response at diagnosis were significantly more likely to experience a local/regional recurrence. These results suggest that HPV16 E6 antibodies may be a potential biomarker for both the HPV-OPC diagnosis and prognosis. This is the largest study to date to assess the sensitivity of HPV16 E6 antibodies for HPV-OPC. Although several small studies (with 4-66 HPV-OPC tumors) have reported the sensitivity of HPV16 E6 serology for HPV-OPC, many have relied on suboptimal methods for assigning the HPV tumor status and/or on unvalidated HPV16 E6 antibody assays. Only 5 studies 9,10,24-26 have measured HPV16 E6 antibody levels with the same highly specific multiplex serology assay used in the prospective studies by Kreimer et al, 3, 4 who reported the initial discovery and validation of HPV16 E6 antibodies as an early marker for OPC. In the largest of these studies, Holzinger et al 9 reported that 63 of 66 HPV16-OPCs evaluated (defined with the research gold-standard method of dual HPV16 DNA/RNA positivity) were HPV16 E6-seropositive (sensitivity, 96%). Taken together, these results as well as our own suggest that the vast majority of patients with HPV16-OPC mount an HPV16 E6 antibody response by the time of their diagnosis.
Five small studies assessed changes in HPV16 E6 antibody levels after treatment among HPV-OPC patients. [5] [6] [7] 10, 27 All 5 reported that HPV16 E6 antibody levels decreased after treatment; 2 reported an association between stable or increasing HPV16 E6 antibody levels and recurrence. 5, 7 In contrast, we did not observe a decrease in HPV16 E6 MFI levels after treatment or an association between changes in HPV16 E6 levels after treatment and recurrence. This may be due to differences in the serologic assays and/or the small number of recurrences among our HPV16 E6-seropositive patients.
We did, however, observe an association between pretreatment HPV16 E6 seronegativity and an increased risk of recurrence. Four prior studies evaluated pretreatment HPV16 E6 levels and the risk of recurrence; all reported different conclusions. 7, 8, 10, 27 A study of 43 HPV-OPC patients found that a log 10 -unit increase in the pretreatment HPV16 E6 antibody level was associated with an increased risk of recurrence (HR, 5.42, 95% CI, 1.1-25.7). 7 In contrast, a study of 96 HPV-OPC patients found that pretreatment HPV16 E6 seropositivity was associated with a 70% decreased risk of recurrence or death (HR, 0.3, 95% CI, 0.1-0.9). 8 Finally, 2 found no association between HPV16 E6 antibody levels and recurrence. 10, 27 These studies are difficult to compare because of the differences in the serologic assays and methods used for assigning the HPV tumor status. A limitation of the previous studies is that they all relied on non-goldstandard methods for assigning the HPV tumor status, and this may have resulted in misclassification. Furthermore, 3 of the 4 studies used enzyme-linked immunosorbent assay (ELISA)-based assays to measure HPV16 E6 antibodies, 7, 8, 27 and these may have lower sensitivity and specificity than the multiplex serologic assay used in the current analysis. Dahlstrom et al 8 previously reported a sensitivity and specificity of 79% and 56%, respectively, of HPV16 E6 seropositivity for HPV-OPC as measured by ELISA.
The strengths of our study include the large sample size and the use of the HPV serologic assay that has shown the highest sensitivity and specificity to date as well as accepted gold-standard methods for assigning the HPV tumor status. By using gold-standard methods, we reduced the potential for misclassification and more precisely assessed the performance of the HPV16 E6 biomarker. However, we had limited power to evaluate changes in posttreatment HPV16 E6 antibodies and the risk of recurrence due to both the low recurrence rate and the limited number of serial samples. In addition, for the aforementioned reasons, we could not conduct multivariate Cox regressions that controlled for important baseline characteristics such as smoking, stage, and treatment.
Taken together, these findings may inform efforts for the early detection, treatment, and posttreatment surveillance of HPV-OPC. Our finding that HPV16 E6 antibodies are present in the majority of patients with HPV-OPC at the time of diagnosis, coupled with the prospective finding that HPV16 E6 antibodies are induced more than 10 years before the diagnosis, suggests that HPV16 E6 antibodies may have potential clinical utility for the early diagnosis of HPV-OPC. These results also suggest that HPV16 E6 antibodies may have potential utility for pretreatment risk stratification, which would allow patients at low risk for recurrence to be safely deescalated and patients at high risk to receive more intensive posttreatment surveillance. Although the multiplex serology assay is currently for research use only, an ELISA-based assay could be developed that would allow HPV16 E6 antibody detection within standard hospitalbased laboratories. However, it is important to note that Original Article additional larger studies using gold-standard methods for the determination of the HPV serology and HPV tumor status are needed to confirm these findings before moving to prospective trials.
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